vs
Side-by-side financial comparison of Beta Bionics, Inc. (BBNX) and DYNEX CAPITAL INC (DX). Click either name above to swap in a different company.
DYNEX CAPITAL INC is the larger business by last-quarter revenue ($43.5M vs $27.6M, roughly 1.6× Beta Bionics, Inc.). On growth, DYNEX CAPITAL INC posted the faster year-over-year revenue change (531.3% vs 56.6%).
Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.
Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.
BBNX vs DX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $43.5M |
| Net Profit | $-21.9M | — |
| Gross Margin | 59.5% | — |
| Operating Margin | -47.4% | — |
| Net Margin | -79.3% | — |
| Revenue YoY | 56.6% | 531.3% |
| Net Profit YoY | 23.6% | — |
| EPS (diluted) | $-0.49 | $1.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.6M | — | ||
| Q4 25 | $32.1M | $43.5M | ||
| Q3 25 | $27.3M | $30.6M | ||
| Q2 25 | $23.2M | $23.1M | ||
| Q1 25 | $17.6M | $17.1M | ||
| Q1 24 | — | $-3.2M | ||
| Q4 22 | — | $6.2M | ||
| Q3 22 | — | $7.1M |
| Q1 26 | $-21.9M | — | ||
| Q4 25 | $-13.5M | — | ||
| Q3 25 | $-14.2M | $150.4M | ||
| Q2 25 | $-16.9M | $-13.6M | ||
| Q1 25 | $-28.7M | $-3.1M | ||
| Q1 24 | — | $40.1M | ||
| Q4 22 | — | $43.3M | ||
| Q3 22 | — | $-46.7M |
| Q1 26 | 59.5% | — | ||
| Q4 25 | 59.0% | — | ||
| Q3 25 | 55.5% | — | ||
| Q2 25 | 53.8% | — | ||
| Q1 25 | 50.9% | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q1 26 | -47.4% | — | ||
| Q4 25 | -50.2% | — | ||
| Q3 25 | -62.5% | — | ||
| Q2 25 | -85.5% | — | ||
| Q1 25 | -105.7% | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q1 26 | -79.3% | — | ||
| Q4 25 | -41.9% | — | ||
| Q3 25 | -52.1% | 491.3% | ||
| Q2 25 | -72.6% | -58.8% | ||
| Q1 25 | -162.5% | -18.0% | ||
| Q1 24 | — | -1256.8% | ||
| Q4 22 | — | 697.2% | ||
| Q3 22 | — | -655.3% |
| Q1 26 | $-0.49 | — | ||
| Q4 25 | $-0.16 | $1.59 | ||
| Q3 25 | $-0.33 | $1.08 | ||
| Q2 25 | $-0.39 | $-0.14 | ||
| Q1 25 | $-0.93 | $-0.06 | ||
| Q1 24 | — | $0.64 | ||
| Q4 22 | — | $0.44 | ||
| Q3 22 | — | $-1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $199.5M | $531.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $271.2M | $2.5B |
| Total Assets | $304.4M | $17.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $199.5M | — | ||
| Q4 25 | $219.1M | $531.0M | ||
| Q3 25 | $228.7M | $491.0M | ||
| Q2 25 | $249.7M | $387.5M | ||
| Q1 25 | $231.5M | $327.4M | ||
| Q1 24 | — | $295.7M | ||
| Q4 22 | — | $332.0M | ||
| Q3 22 | — | $260.4M |
| Q1 26 | $271.2M | — | ||
| Q4 25 | $287.6M | $2.5B | ||
| Q3 25 | $294.8M | $2.0B | ||
| Q2 25 | $301.6M | $1.6B | ||
| Q1 25 | $313.8M | $1.4B | ||
| Q1 24 | — | $958.5M | ||
| Q4 22 | — | $901.3M | ||
| Q3 22 | — | $771.3M |
| Q1 26 | $304.4M | — | ||
| Q4 25 | $328.7M | $17.3B | ||
| Q3 25 | $330.0M | $14.2B | ||
| Q2 25 | $330.0M | $11.3B | ||
| Q1 25 | $338.0M | $9.0B | ||
| Q1 24 | — | $6.3B | ||
| Q4 22 | — | $3.6B | ||
| Q3 22 | — | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $120.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-8.6M | $120.8M | ||
| Q3 25 | $-8.7M | $68.3M | ||
| Q2 25 | $-13.6M | $31.9M | ||
| Q1 25 | $-20.0M | $6.4M | ||
| Q1 24 | — | $-17.1M | ||
| Q4 22 | — | $30.1M | ||
| Q3 22 | — | $25.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-10.5M | — | ||
| Q3 25 | $-10.0M | — | ||
| Q2 25 | $-15.4M | — | ||
| Q1 25 | $-20.3M | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | -32.8% | — | ||
| Q3 25 | -36.7% | — | ||
| Q2 25 | -66.2% | — | ||
| Q1 25 | -115.1% | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | — | ||
| Q3 25 | 4.7% | — | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | 1.9% | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | -0.43× | ||
| Q4 22 | — | 0.69× | ||
| Q3 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
